H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of $40.00. The company's shares closed last Friday at $6.10, close to its 52-week low of $4.56. According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -26.7% and a 20.1% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zymeworks with a $22.56 average price target.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-zymeworks-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Zymeworks Charts.
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Zymeworks Charts.